Russell Investments Group Ltd. cut its position in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 4.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,543 shares of the biotechnology company’s stock after selling 2,546 shares during the quarter. Russell Investments Group Ltd. owned 0.08% of Sarepta Therapeutics worth $3,894,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of SRPT. Arrowstreet Capital Limited Partnership acquired a new stake in Sarepta Therapeutics in the fourth quarter worth $217,000. Aperio Group LLC acquired a new stake in Sarepta Therapeutics in the fourth quarter worth $219,000. Zeke Capital Advisors LLC acquired a new stake in Sarepta Therapeutics in the first quarter worth $241,000. ETRADE Capital Management LLC acquired a new stake in Sarepta Therapeutics in the fourth quarter worth $247,000. Finally, Quantitative Systematic Strategies LLC acquired a new stake in Sarepta Therapeutics in the first quarter worth $261,000. 86.27% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have weighed in on SRPT shares. HC Wainwright increased their target price on Sarepta Therapeutics from $75.00 to $92.00 and gave the stock a “buy” rating in a research report on Monday, March 12th. SunTrust Banks increased their target price on Sarepta Therapeutics to $76.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $91.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, March 14th. BidaskClub lowered Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 29th. Finally, ValuEngine raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $126.50.
In related news, Director Richard Barry sold 75,000 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, June 27th. The stock was sold at an average price of $130.34, for a total transaction of $9,775,500.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 7.90% of the stock is owned by insiders.
Shares of Sarepta Therapeutics opened at $132.18 on Friday, according to Marketbeat Ratings. The firm has a market cap of $8.76 billion, a PE ratio of -80.60 and a beta of 1.35. The company has a current ratio of 13.37, a quick ratio of 12.28 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics Inc has a one year low of $32.80 and a one year high of $176.50.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.23). The business had revenue of $64.60 million for the quarter, compared to analyst estimates of $65.31 million. Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. Sarepta Therapeutics’s revenue for the quarter was up 295.3% on a year-over-year basis. During the same period last year, the business posted ($0.57) earnings per share. sell-side analysts anticipate that Sarepta Therapeutics Inc will post -1.98 EPS for the current year.
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.